NIPT - Non Invasive Prenatal Test - Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure


Non-Invasive Prenatal Test (NIPT) For Trisomy Detects Risks Early and Safely

Testing for potential fetal abnormalities is recommended for all expectant parents. Most commonly, a prenatal trisomy syndrome test is prescribed, then traditionally carried out through a procedure called amniocentesis. But this procedure is not without risk: while the chances of losing the fetus isare small, it remains a concern. In response, Eurofins Biomnis has developed non-invasive prenatal tests (NIPTs) that offer fast and accurate results. The easy-to-administer kits draws genetic analysis from a maternal blood sample. By choosing an NIPT screening test, it can be safely determined whether the risk of fetal defects is high or low, reducing the need for invasive procedures by up to 95%.

When deciding whether traditional prenatal screening for trisomy is worth potential complications, including loss of the foetus, expectant parents can find themselves facing a difficult dilemma. Luckily, there are now safer alternatives to amniocentesis that offer close to 100% accurate risk assessment. Our non-invasive prenatal test is an innovative genetic screening procedure for pregnant women at risk of fetal Patau syndrome, Edward's Syndrome, or Down syndrome. These rapid, reliable and safe kits quickly and effectively detect trisomy 13, 18 and 21, and can be carried out by your healthcare provider. Available starting from only the 10th week of pregnancy, the non-invasive prenatal tests offer expectant parents true peace of mind.

The non-invasive prenatal screening tests offered by EurofinsBiomnis provide effective trisomy syndrome screening by drawing a small maternal blood sample. Aside from maternal DNA, the blood of pregnant women contains fetal DNA originating from the placenta. The identification of fetal DNA in the maternal blood sample, in tandem with a new technology called Next Generation Sequencing that is capable of counting all genetic material sequences in the sample, permits the rapid and accurate detection of abnormalities including fetal Patau syndrome (trisomy 13) and Down syndrome (trisomy 21). With a more than 99% detection rate, this non-invasive prenatal screening option may allow you to limit or forgo invasive testing procedures.

Although patients might assume that trisomy screening is necessarily a complicated procedure, the non-invasive prenatal diagnosis kit developed byEurofins Biomnis is remarkably simple to prescribe and administer. The procedure can be prescribed by your healthcare provider, and you can have the blood test taken at your physician's office or at a Eurofins Biomnis partner laboratory. What's more, it can be prescribed early in your pregnancy, after only 10 weeks of pregnancy. With results of the blood test available in around 7 working days, NIPT byEurofinsBiomnis is an efficient, safe and remarkably accurate non-invasive prenatal testing pregnancy risk option. It has been found to reduce unnecessary invasive sampling by up to 95%.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%